| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PPD | Common Stock | Disposed to Issuer | -$1.68M | -35.4K | -100% | $47.50 | 0 | Dec 8, 2021 | Direct | F1, F2 |
| transaction | PPD | Common Stock | Award | $0 | +25.5K | $0.00 | 25.5K | Dec 8, 2021 | Direct | F1, F3 | |
| transaction | PPD | Common Stock | Disposed to Issuer | -25.5K | -100% | 0 | Dec 8, 2021 | Direct | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PPD | Stock Options (Right to Buy) | Disposed to Issuer | -$7.49M | -231K | -100% | $32.45 | 0 | Dec 8, 2021 | Common Stock | 231K | $15.05 | Direct | F1, F4 |
| transaction | PPD | Stock Options (Right to Buy) | Award | $0 | +33.2K | +16.39% | $0.00 | 236K | Dec 8, 2021 | Common Stock | 33.2K | $10.59 | Direct | F5 |
| transaction | PPD | Stock Options (Right to Buy) | Disposed to Issuer | -$8.71M | -236K | -100% | $36.91 | 0 | Dec 8, 2021 | Common Stock | 236K | $10.59 | Direct | F1, F5 |
| transaction | PPD | Stock Options (Right to Buy) | Disposed to Issuer | -152K | -100% | 0 | Dec 8, 2021 | Common Stock | 152K | $37.22 | Direct | F1, F6 |
David Michael Johnston is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). |
| F2 | At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). |
| F3 | Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. |
| F4 | These options, of which 33,227 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. |
| F5 | These options, of which (i) 199,364 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 33,228 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. |
| F6 | This option, of which (i) 122,624 provided for vesting on the third anniversary of the grant date and (ii) 29,123 provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. |
EVP of Global Clinical Development